Skip to content
Industry Trend
  • Home
  • Digital Assets & Stocks
  • Technology
  • Digital Marketing
  • Business
  • Reviews
  • About/Contact
    • Content Guidelines
    • Meet our Team
  • Advertise
  • Privacy Policy
  • Disclaimer

Posts by Jim Sachs

Avatar photo
About Jim Sachs
Jim is a business and financial writer, who had spent almost his entire life independently reporting on different business ventures with major impact on the US and global economy. Jim places a special focus on examining IPO potentials, tech stocks, biotech stocks all while investing a great part of his early hours to researching and writing on the companies in the US markets. Jim has 10+ years of experience in financial markets.
SI: Is a Silvergate Capital bankrun incoming?

SI: Is a Silvergate Capital bankrun incoming?

Posted by By Jim Sachs January 4, 2023Posted inDigital Assets & Stocks
Silvergate Capital (NYSE:SI) may be a stock that appears to be undervalued and offer a great opportunity for investors. However, a closer examination of the company and its recent activities…
Read More
PYPL: Does PayPal have a bright future ahead?

PYPL: Does PayPal have a bright future ahead?

Posted by By Jim Sachs January 3, 2023Posted inDigital Assets & Stocks
Investing in PayPal (PYPL) stock has become increasingly attractive over the past several months, as the company has seen a surge in share price and investor attention. PayPal has long…
Read More
RSLS: ReShape Lifesciences has a bright future, here’s why

RSLS: ReShape Lifesciences has a bright future, here’s why

Posted by By Jim Sachs January 3, 2023Posted inDigital Assets & Stocks
ReShape Lifesciences (RSLS) is an innovative health solutions company that helps consumers and healthcare providers address obesity and chronic diseases. The company has developed a portfolio of products, programs, and…
Read More
HOTH: Why did Hoth Therapeutics surge today?

HOTH: Why did Hoth Therapeutics surge today?

Posted by By Jim Sachs December 29, 2022Posted inDigital Assets & Stocks
Hoth Therapeutics (HOTH) saw its stock prices surge today, December 27, 2022, after the company announced that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug…
Read More
NVDA: Why Nvidia took a plunge today

NVDA: Why Nvidia took a plunge today

Posted by By Jim Sachs December 27, 2022Posted inDigital Assets & Stocks
Nvidia (NVDA) stock went down sharply today, with shares dropping by more than 3% in early trading and 1.9% by the end of the day. This sudden decline may come…
Read More
Ikaria Lean Belly Juice

Lose Weight with Ikaria Lean Belly Juice: Our Honest Review

Posted by By Jim Sachs December 24, 2022Posted inReviews
Are you looking for a way to lose weight fast and naturally? Have you heard of Ikaria Lean Belly Juice? Here at Ikaria Health, we’ve done our own research on…
Read More
Unbelievable Results: The Red Boost Hard Wood Tonic System 2023 Review!

Unbelievable Results: The Red Boost Hard Wood Tonic System 2023 Review!

Posted by By Jim Sachs December 23, 2022Posted inReviews
Are you looking for a safe and natural way to improve your overall health and wellbeing (hint: The Red Boost Hard Wood Tonic System)? Have you been searching for a…
Read More
MDWD: Why MediWound’s NextBrid treatment could gain FDA approval

MDWD: Why MediWound’s NextBrid treatment could gain FDA approval

Posted by By Jim Sachs December 21, 2022Posted inDigital Assets & Stocks
MediWound’s NexoBrid is a topical burn treatment that could potentially revolutionize how severe burns are treated. It is a safe and effective way to remove damaged tissue from severe thermal…
Read More
CHRS: Coherus BioSciences resubmits Toripalimab, will FDA approve?

CHRS: Coherus BioSciences resubmits Toripalimab, will FDA approve?

Posted by By Jim Sachs December 21, 2022Posted inDigital Assets & Stocks
Coherus BioSciences (CHRS) and Junshi Bioscience have recently submitted a resubmission of their BLA (Biologics License Application) to the FDA (Food and Drug Administration) for their cancer PD-1 inhibitor Toripalimab.…
Read More
PHAT: Could Phantom Pharmaceuticals get FDA Approval for Vonoprazan?

PHAT: Could Phantom Pharmaceuticals get FDA Approval for Vonoprazan?

Posted by By Jim Sachs December 21, 2022Posted inDigital Assets & Stocks
Phantom Pharmaceuticals (NASDAQ: PHAT) recently announced that its drug, Vonoprazan, has been granted priority review by the U.S. Food and Drug Administration (FDA). Vonoprazan is a novel proton pump inhibitor…
Read More

Posts navigation

Previous page 1 2 3 Next page
Copyright © 2023 Industry Trend. All rights reserved.
Scroll to Top